Special populations : אוכלוסיות מיוחדות

Geriatric Use
In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The ratio of oxazaphosphorines to mesna should remain unchanged.

Uromitexan 400 mg contains sodium, but less than 1 mmol (23 mg) sodium per 10 ml.

4.5   Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed. See section 6.2

4.6   Fertility, pregnancy and lactation

As Uromitexan 400 mg is used as a uroprotectant during cytotoxic therapy with oxazaphosphorines, the risk-benefit ratio of this cytotoxic therapy applies with regard to the use of Uromitexan 400 mg during pregnancy and lactation.

Pregnancy
No adequate data is available on the use of mesna during pregnancy. Animal studies have not revealed any embryotoxic or teratogenic effects of mesna (see section 5.3).

Breast-feeding
Breastfeeding is not allowed during treatment with Uromitexan 400 mg.

Fertility
No fertility studies are available on the use of mesna.